Abstract
Treatment with statins represents an essential component both of primary and secondary cardiovascular prevention strategies. However, a proportion of patients cannot reach low-density lipoprotein cholesterol (LDL-C) targets with the highest tolerable dose of a potent statin or is intolerant to statins. Several treatment options are available for these patients. Colesevelam is a relatively new bile acid sequestrant that decreases serum LDL-C levels. Moreover, colesevelam improves glycemic control and seems to be well-tolerated, at least in short-term studies. Therefore, colesevelam seems to be a useful tool for the management of high-risk patients who cannot achieve LDL-C targets with monotherapy with a potent statin.
Keywords: Colesevelam, statin intolerance, glycemic control, multifactorial intervention, type 2 diabetes mellitus.
Current Pharmaceutical Design
Title:Colesevelam: A New and Improved Bile Acid Sequestrant?
Volume: 19 Issue: 17
Author(s): Konstantinos Tziomalos, Asterios Karagiannis, Dimitri P. Mikhailidis and Vasilios G. Athyros
Affiliation:
Keywords: Colesevelam, statin intolerance, glycemic control, multifactorial intervention, type 2 diabetes mellitus.
Abstract: Treatment with statins represents an essential component both of primary and secondary cardiovascular prevention strategies. However, a proportion of patients cannot reach low-density lipoprotein cholesterol (LDL-C) targets with the highest tolerable dose of a potent statin or is intolerant to statins. Several treatment options are available for these patients. Colesevelam is a relatively new bile acid sequestrant that decreases serum LDL-C levels. Moreover, colesevelam improves glycemic control and seems to be well-tolerated, at least in short-term studies. Therefore, colesevelam seems to be a useful tool for the management of high-risk patients who cannot achieve LDL-C targets with monotherapy with a potent statin.
Export Options
About this article
Cite this article as:
Tziomalos Konstantinos, Karagiannis Asterios, Mikhailidis Dimitri P. and Athyros Vasilios G., Colesevelam: A New and Improved Bile Acid Sequestrant?, Current Pharmaceutical Design 2013; 19 (17) . https://dx.doi.org/10.2174/1381612811319170019
DOI https://dx.doi.org/10.2174/1381612811319170019 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Rheumatoid Arthritis: An Autoimmune Disease with Female Preponderance and Cardiovascular Risk Equivalent to Diabetes Mellitus: Role of Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) Low Levels of High Density Lipoprotein Increase the Severity of Cerebral White Matter Changes:Implications for Prevention and Treatment of Cerebrovascular Diseases
Current Alzheimer Research Significance of Pharmacogenetics and Pharmacogenomics Research in Current Medical Practice
Current Drug Metabolism Co-Crystals for Generic Pharmaceuticals: An Outlook on Solid Oral Dosage Formulations
Recent Advances in Drug Delivery and Formulation Metabolic Homeostasis and Colonic Health: the Critical Role of Short Chain Fatty Acids
Current Nutrition & Food Science High Throughput Mutation Screening by Automated Capillary Electrophoresis
Combinatorial Chemistry & High Throughput Screening Role of Vitamin E in Cellular Antioxidant Defense
Current Chemical Biology Stem Cell Implantation for Myocardial Disorders
Current Drug Delivery Phenotypes of Obstructive Sleep Apnea and Direct Targeted Therapy: A Literature Review
Current Respiratory Medicine Reviews Enzymatic Processing of <i>Omega</i> 3 Long Chain Polyunsaturated Fatty Acid Oils
Current Nutrition & Food Science Written Consent to Use the Drug in Children: The Problem of Off-Label Drugs
Current Pharmaceutical Design Mechanisms of Action of Metformin in Type 2 Diabetes and Associated Complications: An Overview
Mini-Reviews in Medicinal Chemistry ATP-Sensitive K+ Channels: Current and Putative Target for the Prevention and Treatment of Cardiovascular Diseases
Vascular Disease Prevention (Discontinued) Bronchiolitis Care in the Hospital
Reviews on Recent Clinical Trials C-Reactive Protein: Interaction with the Vascular Endothelium and Possible Role in Human Atherosclerosis
Current Pharmaceutical Design Treating COPD in Older and Oldest Old Patients
Current Pharmaceutical Design Cell and Gene Therapies in Cardiovascular Disease with Special Focus on the No Option Patient
Current Gene Therapy Cerebrovascular Complications After Heart Transplantation
Current Cardiology Reviews Towards Human on a Chip: Recent Progress and Future Perspective
Micro and Nanosystems The Endocannabinoid System: A Promising Target for the Management of Type 2 Diabetes
Current Protein & Peptide Science